The Pro Medicus (ASX:PME) share price has dropped 8% in 3 days. What's going on?

The dip in Pro Medicus shares is accompanied by a sector-wide sell-off.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in Pro Medicus Limited (ASX: PME) have had a poor run these past few days after falling off a high of $62.48 on 30 November.

There's been no market-sensitive information out of the Pro Medicus camp in this time. But that hasn't stopped investors selling off shares violently. The company opened Monday's session at $55.93 after pre-market trading.

A female health professional has a wide-eyed shocked expression on her face, even behind the face mask.

Image source: Getty Images

What's up with Pro Medicus shares?

Despite the recent weakness, shares in the health imaging IT provider were a standout performer in November. They closed out the month 17% in the green – well ahead of most healthcare majors.

However, the dip in Pro Medicus shares is accompanied by a sector-wide sell-off. This sell-off has been in situ since we rolled into December.

For instance, the S&P/ASX 200 Health Care Index (XHJ) has slipped 5% since the end of November, and shows no sign of slowing from the open today.

Concern around the Omicron COVID-19 variant and frothy share markets around the world has many investors taking risk off the table and seeking more defensive positions in safer assets, according to recent analysis from Goldman Sachs and JP Morgan.

Goldman has even lowered its 2022 US GDP forecasts from 4.2% to 3.8%, citing risks and potential impacts of the new strain, according to reporting from Bloomberg Intelligence.

This activity appears to have boded poorly for ASX health care shares, Pro Medicus included.

Although, the team at investment bank Citi reckons the pullback in the company's share price is warranted.

The firm rates Pro Medicus a sell at $45/share and reckons that investors could be overly optimistic in their growth projections for the company.

Citi notes the presence of many substitute products from Pro Medicus' competitors that could originate in future. This poses a threat to the company's profits and could compress its margins going forward, the broker says.

In the absence of any price-sensitive information out of the company's camp lately, it appears that weakness in the wider sector has spilled over into names like Pro Medicus as a negative catalyst to its share price.

Pro Medicus share price snapshot

In the past 12 months the Pro Medicus share price has climbed more than 90%. Pro Medicus shares have rallied 67% this year to date.

However, they have taken a backward step in the last month and are almost 7% in the red. The Pro Medicus share price has fallen 6.65% in just the last week of trading.

The author has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended SDI Limited and Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Female scientist working in a laboratory.
Healthcare Shares

This ASX biotech stock could deliver 40%-plus returns Morgans says

This small company continues to kick goals.

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Healthcare Shares

How high could Cochlear shares bounce back? Brokers disagree

Despite bad news on the earnings front this week, Cochlear shares could still deliver upside.

Read more »

Retired couple hugging and laughing.
Healthcare Shares

A Budget announcement has put a rocket under this ASX aged care provider's shares

A shake up in the funding model will be a boost for this company.

Read more »

An arrow crashes through the ground as a businessman watches on.
Healthcare Shares

Cochlear stock down 40%: How much has this cost ASX investors?

One day can ruin years of success...

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

What on earth's going on with Pro Medicus shares?

The quality stock is now driven heavily by expectations.

Read more »

A stressed businessman sits next to his briefcase with his head in his hands, while the ASX boards behind him show shares crashing.
52-Week Lows

CSL's collapse deepens. Why this ASX giant can't find a floor

CSL shares hit a 9-year low as new demand concerns emerge.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Prediction: CSL shares could surpass $265 in 2026

CSL shares are tumbling again on Wednesday. Here's what it'll take for the price to take a u-turn.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

Why are Cochlear shares down 36% today?

The medical device manufacturer has delivered a bitter pill for shareholders.

Read more »